PCSK9
Assets acting on this target.
- Class
- PCSK9-targeted therapeutic
PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein secreted mainly by the liver that regulates how many low-density lipoprotein receptors (LDLRs) appear on the surface of liver cells. LDLRs are responsible for pulling LDL cholesterol ('bad cholesterol') out of the bloodstream. Normally, after an LDLR captures a cholesterol particle, it recycles back to the cell surface to work again. PCSK9 binds to the LDLR and redirects it toward destruction instead, reducing the number of receptors available and leaving more LDL cholesterol circulating in blood. People with naturally occurring PCSK9 loss-of-function variants have lifelong low LDL cholesterol and reduced rates of atherosclerotic cardiovascular disease, while gain-of-function variants cause a hereditary form of very high cholesterol. This genetic evidence established PCSK9 as a rational drug target: blocking its activity or reducing its production allows more LDLR to persist, increasing clearance of LDL cholesterol from the blood. Because elevated LDL cholesterol is a major driver of atherosclerosis, heart attack, and stroke, PCSK9-targeted therapies are used, often alongside other cholesterol-lowering treatments, to bring LDL cholesterol down further in people at cardiovascular risk.
By indication
Related mechanisms
PCSK9 drugs compared
19 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| AlirocumabPraluent | Regeneron Pharmaceuticals, Sanofi | monoclonal antibody | Approved | Approved in Atherosclerotic Cardiovascular Disease; Approved in Homozygous Familial Hypercholesterolemia |
| EvolocumabRepatha | Amgen | monoclonal antibody | Approved | Approved in Atherosclerotic Cardiovascular Disease; Approved in Homozygous Familial Hypercholesterolemia |
| InclisiranLeqvio | Alnylam Pharmaceuticals, Novartis | RNAi (siRNA) | Approved | Approved in Homozygous Familial Hypercholesterolemia; Phase 3 in Atherosclerotic Cardiovascular Disease |
| Ebronucimab | Akeso, Hubei Jumpcan Pharmaceutical | monoclonal antibody | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease |
| EnlicitideLipfendra | Merck & Co. | peptide | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease; Phase 3 in Hypercholesterolemia |
| Laroprovstat | AstraZeneca | small molecule | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease; Phase 2 in Dyslipidemia |
| LerodalcibepLerochol | Everest Medicines (Beijing) Co., Ltd., LIB Therapeutics, Sun Pharmaceutical Industries | small protein (recombinant fusion protein) | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease |
| OngericimabJunshida | Shanghai Junshi Bioscience | monoclonal antibody | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease |
| QLC7401 | Qilu Pharmaceutical, Suzhou Ribo Life Science | RNAi (siRNA) | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease |
| Recaticimab | Jiangsu Hengrui Pharmaceuticals | monoclonal antibody | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease |
| SAL003 | Shenzhen Salubris Pharmaceuticals | monoclonal antibody | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease |
| SYH2053 | CSPC Pharmaceutical Group | RNAi (siRNA) | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease |
| TafolecimabSintbilo | Innovent Biologics | monoclonal antibody | Phase 3 | Phase 3 in Atherosclerotic Cardiovascular Disease |
| DNV001 | Hangzhou Dinovate Biotech | RNAi (siRNA) | Phase 2 | Phase 2 in Atherosclerotic Cardiovascular Disease |
| HRS-1301 | Jiangsu Hengrui Pharmaceuticals | small molecule | Phase 2 | Phase 2 in Atherosclerotic Cardiovascular Disease; Phase 2 in Hyperlipidemia |
| COR-1004 | Corsera Health | Not recorded | Phase 1 | Phase 1 in Atherosclerotic Cardiovascular Disease |
| HS-10510 | Hansoh Pharmaceutical Group | small molecule | Phase 1 | Phase 1 in Atherosclerotic Cardiovascular Disease |
| RBD7022 | Suzhou Ribo Life Science | RNAi (siRNA) | Phase 1 | Phase 1 in Atherosclerotic Cardiovascular Disease |
| RN0191 | Rona Therapeutics | RNAi (siRNA) | Phase 1 | Phase 1 in Atherosclerotic Cardiovascular Disease |